The development of antisense oligonucleotides (ASOs) is showing promise in therapeutic applications for a number of diseases, both neurological and non-neurological. The accurate quantification of ASOs in complex biological tissues requires robust and sensitive bioanalytical assays that minimize interference, an area in which Altasciences has significant expertise.
In this issue of The Altascientist we provide an overview of the evolving ASO therapeutic approach, and present two case studies demonstrating our capabilities in the field.
|